Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Is lanthanum carbonate safer and more effective than calcium carbonate for hyperphosphatemia in dialysis patients?

Nature Clinical Practice Nephrology volume 1, pages 20–21 (2005)Cite this article

boxed-textHutchison AJ et al. (2005) Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate. Nephron Clin Pract 100: c8–c19

Lanthanum carbonate is a highly effective phosphate binder associated with a lower risk of hypercalcemia and systemic accumulation than calcium-based phosphate-binding agents

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Block GA et al. (2004) Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15: 2208–2218

    Article  CAS  Google Scholar 

  2. Sheikh MS et al. (1989) Reduction of dietary phosphorus absorption by phosphorus binders. A theoretical, in vitro, and in vivo study. J Clin Invest 83: 66–73

    Article  CAS  Google Scholar 

  3. D'Haese PC et al. (2003) A multicenter study on the effects of lanthanum carbonate (Fosrenol™) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int 63 (Suppl 85): S73–S78

    Article  Google Scholar 

  4. Behets GJ et al. (2004) Does the phosphate binder lanthanum carbonate affect bone in rats with chronic renal failure? J Am Soc Nephrol 15: 2219–2228

    Article  CAS  Google Scholar 

  5. Lacour B et al. (2005) Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration. Kidney Int 67: 1062–1069

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Chloe Harman, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Associate Professor, and Director of the Division of Nephrology and Dialysis Center, Kobe University School of Medicine, Kobe, Japan

    Masafumi Fukagawa

Authors
  1. Masafumi Fukagawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Masafumi Fukagawa.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fukagawa, M. Is lanthanum carbonate safer and more effective than calcium carbonate for hyperphosphatemia in dialysis patients?. Nat Rev Nephrol 1, 20–21 (2005). https://doi.org/10.1038/ncpneph0020

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpneph0020

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing